Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Moderna and Merck sustain 49% risk reduction in milestone five-year cancer vaccine study

Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) announced Tuesday that their individualized neoantigen therapy continues to show dramatic long-term benefits, providing the strongest evidence to date that mRNA technology can be harnessed to treat established cancer.

Leia mais: Moderna and Merck sustain 49% risk reduction in milestone five-year cancer vaccine study